EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Lytton Leaves VC Firm for Biogen

Michael Lytton has left his post as general partner at Boston venture firm Oxford Bioscience Partners to be executive vice president of business development at Cambridge, MA-based biotech powerhouse Biogen Idec (NASDAQ:BIIB), according to a press release. Lytton, a well-known venture capitalist who joined Oxford in 2001, will now be on the opposite side of deal talks from where he has sat as a board member with public and private life sciences startups in Oxford’s portfolio. A Biogen spokeswoman said that Lytton started work for the company today.

By posting a comment, you agree to our terms and conditions.